Hemostemix (CVE:HEM) Stock Price Up 29.4% – Here’s What Happened
by Scott Moore · The Cerbat GemHemostemix Inc. (CVE:HEM – Get Free Report)’s stock price shot up 29.4% during trading on Friday . The stock traded as high as C$0.11 and last traded at C$0.11. 602,760 shares were traded during trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.
Hemostemix Stock Up 29.4%
The firm has a market cap of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25. The company has a 50-day simple moving average of C$0.09 and a 200-day simple moving average of C$0.10. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.